===Ariad Pharma (ARIA) to be acquired by Takeda (TKPYY) for $24/share or $5.2 bln
Ariad Pharma to be acquired by Takeda (TKPYY) for $24/share in cash, or approximately $5.2 bln : The transaction is a compelling opportunity for Takeda shareholders. It will provide immediate revenue, bring considerable long-term revenue potential and deliver synergy savings. ARIAD provided calendar year 2016 revenue guidance for Iclusig of $170-180 million, and Takeda expects significant long-term revenue potential from the two lead assets. Takeda projects the acquisition of ARIAD to be accretive to Underlying Core Earnings by FY2018 and broadly neutral in FY2017. Strong revenue growth and synergy savings will offset increased sales and marketing costs for the brigatinib launch. The transaction is expected to close by the end of February 2017.
No comments:
Post a Comment